abrdn Life Sciences Investors (HQL) Competitors $16.16 +0.16 (+1.00%) Closing price 03:59 PM EasternExtended Trading$16.18 +0.02 (+0.09%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HQL vs. BCAT, OXLC, CET, GSBD, MFIC, NMFC, AWF, HQH, ASA, and BBDCShould you be buying abrdn Life Sciences Investors stock or one of its competitors? The main competitors of abrdn Life Sciences Investors include BlackRock Capital Allocation Term Trust (BCAT), Oxford Lane Capital (OXLC), Central Securities (CET), Goldman Sachs BDC (GSBD), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), AllianceBernstein Global High Income Fund (AWF), abrdn Healthcare Investors (HQH), ASA Gold and Precious Metals (ASA), and Barings Bdc (BBDC). These companies are all part of the "financial services" industry. abrdn Life Sciences Investors vs. Its Competitors BlackRock Capital Allocation Term Trust Oxford Lane Capital Central Securities Goldman Sachs BDC MidCap Financial Investment New Mountain Finance AllianceBernstein Global High Income Fund abrdn Healthcare Investors ASA Gold and Precious Metals Barings Bdc BlackRock Capital Allocation Term Trust (NYSE:BCAT) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap financial services companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Which has preferable earnings and valuation, BCAT or HQL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlackRock Capital Allocation Term Trust$159.64M10.01N/AN/AN/Aabrdn Life Sciences InvestorsN/AN/AN/AN/AN/A Which has more risk and volatility, BCAT or HQL? BlackRock Capital Allocation Term Trust has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, abrdn Life Sciences Investors has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Is BCAT or HQL a better dividend stock? BlackRock Capital Allocation Term Trust pays an annual dividend of $3.37 per share and has a dividend yield of 22.7%. abrdn Life Sciences Investors pays an annual dividend of $1.82 per share and has a dividend yield of 11.3%. Does the media refer more to BCAT or HQL? In the previous week, BlackRock Capital Allocation Term Trust's average media sentiment score of 1.97 beat abrdn Life Sciences Investors' score of 0.00 indicating that BlackRock Capital Allocation Term Trust is being referred to more favorably in the media. Company Overall Sentiment BlackRock Capital Allocation Term Trust Very Positive abrdn Life Sciences Investors Neutral Do institutionals and insiders believe in BCAT or HQL? 36.1% of BlackRock Capital Allocation Term Trust shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is BCAT or HQL more profitable? Company Net Margins Return on Equity Return on Assets BlackRock Capital Allocation Term TrustN/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A SummaryBlackRock Capital Allocation Term Trust beats abrdn Life Sciences Investors on 4 of the 6 factors compared between the two stocks. Get abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HQL vs. The Competition Export to ExcelMetricabrdn Life Sciences InvestorsFIN IndustryFinance SectorNYSE ExchangeMarket Cap$461.96M$4.02B$12.42B$21.49BDividend Yield11.38%6.16%5.63%3.67%P/E RatioN/AN/A29.9529.66Price / SalesN/A24.3229.9086.41Price / CashN/A16.9219.3417.79Price / BookN/A1.292.274.63Net IncomeN/A$187.53M$1.02B$1.01B7 Day Performance3.06%0.17%-1.20%-1.84%1 Month Performance14.25%1.30%-1.32%0.55%1 Year Performance8.82%3.71%541.23%13.45% abrdn Life Sciences Investors Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HQLabrdn Life Sciences InvestorsN/A$16.16+1.0%N/A+7.7%$461.96MN/A0.00N/ABCATBlackRock Capital Allocation Term TrustN/A$14.79+0.9%N/A-10.5%$1.59B$159.64M0.00147,000Positive NewsOXLCOxford Lane Capital1.5974 of 5 stars$16.68-1.4%N/A-37.8%$1.51B$57.31M4.02601Positive NewsCETCentral SecuritiesN/A$51.50-0.2%N/A+9.0%$1.49B$222.17M0.006Positive NewsGSBDGoldman Sachs BDC2.0513 of 5 stars$10.76-1.2%$10.00-7.0%-29.1%$1.24B$434.37M8.54N/AMFICMidCap Financial Investment2.9635 of 5 stars$11.96-0.7%$13.30+11.2%-14.5%$1.12B$108.70M11.07N/ANMFCNew Mountain Finance3.0655 of 5 stars$9.65-0.7%$10.60+9.8%-23.7%$1.03B$371.67M12.70N/AAnalyst ForecastAWFAllianceBernstein Global High Income FundN/A$11.22+0.1%N/A-1.5%$966.64M$70.19M0.00N/AHQHabrdn Healthcare InvestorsN/A$17.95+1.0%N/A+1.8%$957.13MN/A0.00147,000Positive NewsASAASA Gold and Precious MetalsN/A$45.66+2.8%N/A+121.4%$956.33MN/A0.001,100Positive NewsGap UpBBDCBarings Bdc2.423 of 5 stars$8.81-1.6%$9.67+9.8%-13.7%$941.17M$286.17M9.1726Dividend Announcement Related Companies and Tools Related Companies BCAT Competitors OXLC Competitors CET Competitors GSBD Competitors MFIC Competitors NMFC Competitors AWF Competitors HQH Competitors ASA Competitors BBDC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HQL) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
